TNFi
This drug is selected. Its supporting articles are shown below.
Articles mentioning TNFi
9 articles · page 1 of 1…ent for immune-mediated inflammatory diseases (IMIDs). However, TNFi therapy causes a faster waning of antibody responses following …
…nt started a b/tsDMARD (abatacept: 242, IL-6Ri: 317, JAKi: 333, rituximab: 176, TNFi: 874). Compared with the wrist, all joints demonstra…
…).Conclusion We found no evidence for a better effectiveness of TNFi in patients with very early versus established axSpA.…
…0.91) and fibrosis or cirrhosis (HR 0.81; 95% CI 0.70 to 0.92). IL-17i (4579 matched pairs) and TNFi (15 007 matched pairs) treatment …
…n for missing data. Pairwise comparisons were performed between IXE and tumour necrosis factor inhibitors (TNFi), secukinumab (SEC)…
…is (PsA) with a clinical indication for treatment escalation of methotrexate (MTX) (ie, non-response or intolerance to MTX) to a b-DMARD are…
…ent followed by another anti-TNFa treatment or Vedolizumab then Ustekinumab. Median age at diagnosis was 8 years. We found that (40%) switc…
…1.38), TNFi 1.01 (0.66 to 1.54), rituximab 1.14 (0.71 to 1.84), tocilizumab 1.48 (0.92 to 2.40). LDA and remission rates were unaffected by…